Guideline & source register

PDF served from fogsi.org (2026 upload path) — definitions, HDP-Gestosis score, treatment threshold ≥140/90 (WOG), targets ≤140/90, delivery timing (GH term; mild PE 37 wks; severe PE after 34 wks; eclampsia deliver once stabilised post-MgSO4; ≤24 wks immediate delivery better; individualise 24–33+6)

Full PDF: standardised BP measurement; proteinuria PrCr ≥30 mg/mmol, ACR ≥8 mg/mmol or ≥300 mg/day or dipstick 2+ if confirmatory testing unavailable; no 'mild/severe' PE label in ongoing pregnancy; treat all HDP with antihypertensives; severe HTN ≥160/110 treat within minutes-hours monitored; target DBP 85; MgSO4 for eclampsia + PE with severe HTN/neuro features; aspirin ≥150 mg night from <16 to 36 wks after multivariable screening; calcium <900 mg/d intake → supplement ≥500 mg/d; exercise recommended; LMWH/vitC/E/folate NOT for PE prevention

Publisher summary + independent 2025 review confirming advisory remains operative: initiate/titrate therapy at ≥140/90 mmHg for chronic HTN (treatment threshold, not target). Note ACOG PB222 base document last reaffirmed — verify current reaffirmation date when next audited.

WHO pages + NCBI compendium: daily IFA 30–60 mg elemental iron + 400 µg folic acid; intermittent IFA only where daily not acceptable & anaemia prevalence <20%; anaemia in ANC → 120 mg elemental iron daily until Hb normal; MMS recommended only within rigorous research contexts (supersedes 2016); ≥8 contacts

Targeted recheck: WHO 2025 recognition/treatment trigger (≥500 mL or ≥300 mL with abnormal haemodynamics), concurrent first-response bundle and refractory-haemorrhage fibrinogen target ≥2 g/L if replacing a level <2 g/L. Primary recommendation chapter/table indexed at https://www.ncbi.nlm.nih.gov/books/NBK619233/ ; direct access currently presents a browser check. This is a scoped primary-text/summary check, not a new full-document clinical certification.

NICE overview + Update information page (dates above confirmed)

CDC pages + wall chart: uncomplicated gonorrhoea cervix/urethra/rectum → ceftriaxone 500 mg IM single dose (<150 kg; 1 g if ≥150 kg); pharyngeal same; conjunctivitis 1 g IM; DGI 1 g IV/IM q24h; PID outpatient → ceftriaxone 500 mg IM ×1 + doxycycline 100 BD ×14 d + metronidazole 500 BD ×14 d; chlamydia doxycycline 100 BD ×7 d (pregnancy → azithromycin); trichomonas metronidazole 500 mg BD ×7 d (women); bacterial vaginosis metronidazole 500 BD ×7 d etc.; test-of-cure/retest intervals per section; EPT provisions US-specific (not applicable India)

RCOG page incl. June 2022 update note aligning steroids advice with GTG 74 (offer up to 33+6; consider to 35+6 with caution per GTG74 Feb 2022)

Cited via RCOG GTG73 update note; direct PDF audit pending — flag

RCOG listing confirms 3rd edition current + replacement in development (quarterly update page)

Official Gazette text + SCC/LiveLaw notifications; Section 5A confidentiality (disclosure punishable up to 1 yr); place-of-performance restriction s.4; failure-of-device presumption explanation; rape anguish presumption Explanation 2

FIGO announcement + PubMed abstract with full substage definitions

ESGO guidelines portal + Lancet Oncology abstract + pocket-guideline content (risk-group tables, molecular-classification requirements, adjuvant strategy)

Guideline recommendation extracts: letrozole first-line pharmacological ovulation induction (off-label caveat); clomiphene > metformin alone; gonadotrophins second line low-dose step-up; laparoscopic ovarian surgery alternative second line; IVF after failed 1st/2nd line with antagonist protocol + agonist trigger/freezing strategy for OHSS risk reduction; psychological screening; metabolic/CVD/sleep surveillance; inositol experimental

TXA 1 g IV over 10 minutes within three hours of birth; repeat 1 g for bleeding continuing at 30 minutes or recurring within 24 hours. The recurrence rule is for a second dose and does not permit a first dose beyond three hours. WHO 2025 recommendation text and original WHO dosing reviewed.

WHO landing page; detailed wording pending full-text audit — flagged in module

Landing page; dose specifics via Consolidated 2025 chapter + provider guide (oxytocin 10 IU IM/IV)

RCOG Green-top index shows 10a archived; app therefore uses FOGSI-HDP-2026 + ISSHP-2021 + NICE NG121-era principles instead

Independent peer-reviewed comparison table (Clin Hypertens 2025): initiate drugs ≥140/90; targets SBP <140, DBP 80–90

Journal page incl. cross-guideline threshold tables

Presence on current RCOG index only — FULL TEXT AUDIT REQUIRED before relying on thresholds (marked in-app)

Full primary guideline checked for existing/new levothyroxine dosing, TFT follow-up, lowest-effective-dose antithyroid treatment, no routine block-and-replace and considering PTU→carbimazole after 20 weeks; conversion PTU:carbimazole 20:1. May 2026 correction https://obgyn.onlinelibrary.wiley.com/doi/10.1111/1471-0528.70259 checked: fetal monthly scans start at 26–28 weeks onwards; CMZ abbreviation correction. Levothyroxine tablet preparation/interactions cross-checked against https://www.medicines.org.uk/emc/product/12781/smpc .

Scope: additional clinical-detail explanation for pul. Checked the assessment, management-decision and follow-up statements in that section against this source. This does not certify all pre-existing regimens, calculations or recommendations in the module. Also checked ultrasound repeat-scan/second-opinion criteria before diagnosing miscarriage. Additional admission/discharge check 18 October 2026 (limited to the following): PUL discharge uncertainty, symptoms over hCG, paired hCG close to 48 hours but not earlier, written 24-hour contact and tracked repeat assessment.

Scope: additional clinical-detail explanation for ectopic-pregnancy. Checked the assessment, management-decision and follow-up statements in that section against this source. This does not certify all pre-existing regimens, calculations or recommendations in the module. Also corrected stable-tubal-ectopic selection and follow-up descriptions, without certifying all rare-site regimens. Additional admission/discharge check 18 October 2026 (limited to the following): Outpatient eligibility versus rupture/pain/surgical criteria; expectant days 2/4/7, methotrexate days 4/7 then weekly; salpingotomy day 7 then weekly; salpingectomy urine test at 3 weeks.

Scope: additional clinical-detail explanation for miscarriage-management. Checked the assessment, management-decision and follow-up statements in that section against this source. This does not certify all pre-existing regimens, calculations or recommendations in the module. Also checked the missed/incomplete miscarriage drug rows and the scan-confirmed intrauterine-pregnancy progesterone criterion with continuation to 16 completed weeks when a heartbeat is confirmed. Additional admission/discharge check 18 October 2026 (limited to the following): Expectant reassessment at 7–14 days, urine test at 3 weeks, medical-treatment no bleeding within 48 hours/contact and persistent symptoms/positive test reassessment.

Scope: additional clinical-detail explanation for recurrent-miscarriage. Checked the assessment, management-decision and follow-up statements in that section against this source. This does not certify all pre-existing regimens, calculations or recommendations in the module.

Scope: additional clinical-detail explanation for sti-chlamydia. Checked the assessment, management-decision and follow-up statements in that section against this source. This does not certify all pre-existing regimens, calculations or recommendations in the module. Additional admission/discharge check 18 October 2026 (limited to the following): Pregnancy test of cure about 4 weeks and retest at 3 months; partner treatment, adherence and persistent symptoms.

Scope: additional clinical-detail explanation for sti-gonorrhoea. Checked the assessment, management-decision and follow-up statements in that section against this source. This does not certify all pre-existing regimens, calculations or recommendations in the module. Additional admission/discharge check 18 October 2026 (limited to the following): Pharyngeal test of cure 7–14 days and reinfection test at 3 months; disseminated illness/PID requires specialist hospital assessment.

Scope: additional clinical-detail explanation for sti-syphilis. Checked the assessment, management-decision and follow-up statements in that section against this source. This does not certify all pre-existing regimens, calculations or recommendations in the module. Additional admission/discharge check 18 October 2026 (limited to the following): Stage-correct treatment completion and timed serological follow-up, neonatal handover and Jarisch–Herxheimer/obstetric warning advice.

Scope: additional clinical-detail explanation for sti-hsv. Checked the assessment, management-decision and follow-up statements in that section against this source. This does not certify all pre-existing regimens, calculations or recommendations in the module. Medication audit: acyclovir 400 mg three times/day for first episode 7–10 days and pregnancy suppression from 36 weeks to birth; non-elimination of neonatal risk. Additional admission/discharge check 18 October 2026 (limited to the following): Severe/disseminated or neurological illness, oral-treatment feasibility, late-pregnancy/birth and neonatal precautions.

Scope: additional clinical-detail explanation for vaginitis. Checked the assessment, management-decision and follow-up statements in that section against this source. This does not certify all pre-existing regimens, calculations or recommendations in the module. Additional admission/discharge check 18 October 2026 (limited to the following): Return for persistent/recurrent symptoms and reassess alternative diagnoses; no routine hospital stay for uncomplicated vaginitis.

Scope: additional clinical-detail explanation for vaginitis. Checked the assessment, management-decision and follow-up statements in that section against this source. This does not certify all pre-existing regimens, calculations or recommendations in the module. Additional admission/discharge check 18 October 2026 (limited to the following): Persistent/recurrent/complicated symptoms and pregnancy-appropriate therapy, without a generic antibiotic discharge course.

Scope: additional clinical-detail explanation for vaginitis. Checked the assessment, management-decision and follow-up statements in that section against this source. This does not certify all pre-existing regimens, calculations or recommendations in the module. Additional admission/discharge check 18 October 2026 (limited to the following): Partner management and retesting sexually active women at about 3 months; recurrence reassessment.

Scope: additional clinical-detail explanation for pid. Checked the assessment, management-decision and follow-up statements in that section against this source. This does not certify all pre-existing regimens, calculations or recommendations in the module. Additional admission/discharge check 18 October 2026 (limited to the following): All CDC hospitalisation indications, especially pregnancy/TOA/severe illness; oral transition after 24–48 hours clinical improvement, TOA >24-hour hospital observation, 14-day total course, response within 72 hours and GC/CT retest at 3 months.

Scope: additional clinical-detail explanation for aub, fibroids. Checked the assessment, management-decision and follow-up statements in that section against this source. This does not certify all pre-existing regimens, calculations or recommendations in the module. Additional admission/discharge check 18 October 2026 (limited to the following): Heavy-bleeding assessment, CBC/structural cause and specialist referral/result tracking when severe or unsuccessful treatment; general recovery used with the separate surgical source.

Scope: additional clinical-detail explanation for endometriosis. Checked the assessment, management-decision and follow-up statements in that section against this source. This does not certify all pre-existing regimens, calculations or recommendations in the module. Additional admission/discharge check 18 October 2026 (limited to the following): Persistent pain, treatment-response and specialist/endometriosis referral; surgery/pathology/fertility follow-through rather than an automatic fixed follow-up interval.

Scope: additional clinical-detail explanation for pcos. Checked the assessment, management-decision and follow-up statements in that section against this source. This does not certify all pre-existing regimens, calculations or recommendations in the module. Medication check 17 October 2026: metabolic metformin indication, 500 mg increments every 1–2 weeks, suggested adult 2.5 g/day/adolescent 2 g/day limits, B12 risk and letrozole first-line fertility indication. Additional admission/discharge check 18 October 2026 (limited to the following): Outpatient metabolic/cycle/endometrial-protection care, abnormal bleeding and fertility-treatment complication triage. OHSS admission/recovery uses the distinct RCOG reference.

Scope: additional clinical-detail explanation for urogynaecology-core. Checked the assessment, management-decision and follow-up statements in that section against this source. This does not certify all pre-existing regimens, calculations or recommendations in the module. Additional admission/discharge check 18 October 2026 (limited to the following): Catheter/emptying and postoperative complication review; stress-incontinence surgery follow-up within 6 months and prolapse review at 6 months with relevant vaginal/mesh assessment; urgent problems need earlier review.

Scope: additional clinical-detail explanation for menopause. Checked the assessment, management-decision and follow-up statements in that section against this source. This does not certify all pre-existing regimens, calculations or recommendations in the module. Additional admission/discharge check 18 October 2026 (limited to the following): Treatment review at 3 months then annually, earlier for concerns; postmenopausal/unscheduled bleeding investigation and individual HRT/endometrial-protection review.

Scope: additional clinical-detail explanation for contraception. Checked the assessment, management-decision and follow-up statements in that section against this source. This does not certify all pre-existing regimens, calculations or recommendations in the module. Additional admission/discharge check 18 October 2026 (limited to the following): Method selection by clinical eligibility; contraception is generally outpatient, with urgent assessment for pain/ectopic/perforation/serious complications.

Scope: additional clinical-detail explanation for infertility-female. Checked the assessment, management-decision and follow-up statements in that section against this source. This does not certify all pre-existing regimens, calculations or recommendations in the module. Additional admission/discharge check 18 October 2026 (limited to the following): Outpatient infertility assessment and appropriate partner/specialty pathways; OHSS aftercare uses the distinct RCOG source, not an inferred NG257 discharge protocol.

Scope: additional clinical-detail explanation for infertility-female. Checked the assessment, management-decision and follow-up statements in that section against this source. This does not certify all pre-existing regimens, calculations or recommendations in the module. Additional admission/discharge check 18 October 2026 (limited to the following): Assigning investigation/viral-test results and the appropriate fertility/specialty reviewer; no universal inpatient infertility workup.

Scope: additional clinical-detail explanation for gdm, pregestational-diabetes. Checked the assessment, management-decision and follow-up statements in that section against this source. This does not certify all pre-existing regimens, calculations or recommendations in the module. Subsequent diagnostic/dependency check: fasting 75 g OGTT thresholds (fasting ≥5.6 or two-hour ≥7.8 mmol/L), nutrition/metformin/insulin choice, immediate insulin at fasting ≥7.0 mmol/L, glucose targets in labour and uncomplicated-GDM birth by 40+6 weeks; distinguish from the Indian non-fasting programme. Additional checked dependencies: India versus NICE growth/birth/labour/postpartum schedules displayed; preconception HbA1c below 6.5% if safe, booking/later risk assessment versus glucose monitoring, renal assessment without pregnancy eGFR, uncomplicated pre-existing-diabetes birth at 37+0–38+6, individual postpartum insulin reduction, and macrosomia birth counselling. Additional admission/discharge check 18 October 2026 (limited to the following): Pregnancy DKA/severe hypoglycaemia admission, GDM stop treatment immediately after birth versus reduce/continue pre-existing insulin, glucose before community transfer and postpartum testing/follow-up. Neonatal assessment remains separate.

Scope: additional clinical-detail explanation for hyperemesis-gravidarum. Checked the assessment, management-decision and follow-up statements in that section against this source. This does not certify all pre-existing regimens, calculations or recommendations in the module.

Scope: additional clinical-detail explanation for icp. Checked the assessment, management-decision and follow-up statements in that section against this source. This does not certify all pre-existing regimens, calculations or recommendations in the module. Additional admission/discharge check 18 October 2026 (limited to the following): Individual repeat blood testing and birth plan; 6-week postpartum symptom/liver/bile-acid reassessment and referral for persistence; most women do not need vitamin K.

Scope: additional clinical-detail explanation for vte. Checked the assessment, management-decision and follow-up statements in that section against this source. This does not certify all pre-existing regimens, calculations or recommendations in the module.

Scope: additional clinical-detail explanation for iol, prom-term. Checked the assessment, management-decision and follow-up statements in that section against this source. This does not certify all pre-existing regimens, calculations or recommendations in the module. Additional admission/discharge check 18 October 2026 (limited to the following): Specifically selected outpatient dinoprostone/mechanical induction, full assessment, exact return/review and emergency instructions; not a general home oxytocin or repeat-dose protocol.

Scope: additional clinical-detail explanation for lscs, vbac-tolac. Checked the assessment, management-decision and follow-up statements in that section against this source. This does not certify all pre-existing regimens, calculations or recommendations in the module. Additional admission/discharge check 18 October 2026 (limited to the following): Selected afebrile uncomplicated caesarean recovery may be offered UK discharge after 24 hours with home follow-up; pain, wound/bladder/mobility/VTE assessment; paracetamol plus NSAID unless contraindicated; breastfeeding codeine caution. The 24-hour option is explicitly not automatic Indian discharge clearance.

Scope: additional clinical-detail explanation for breech-ecv. Checked the assessment, management-decision and follow-up statements in that section against this source. This does not certify all pre-existing regimens, calculations or recommendations in the module. Additional admission/discharge check 18 October 2026 (limited to the following): Same-day home care commonly possible after reassuring post-ECV monitoring; bleeding/pain/fetal concerns, anti-D assessment and subsequent presentation/birth plan.

Scope: additional clinical-detail explanation for shoulder-dystocia. Checked the assessment, management-decision and follow-up statements in that section against this source. This does not certify all pre-existing regimens, calculations or recommendations in the module. Additional admission/discharge check 18 October 2026 (limited to the following): Maternal trauma/haemorrhage and newborn injury assessment after resolution; explanation, support and future-birth counselling.

Scope: additional clinical-detail explanation for cord-prolapse. Checked the assessment, management-decision and follow-up statements in that section against this source. This does not certify all pre-existing regimens, calculations or recommendations in the module. Additional admission/discharge check 18 October 2026 (limited to the following): Urgent birth/neonatal support and post-event explanation; home care follows actual maternal operation/trauma and newborn outcomes.

Scope: additional clinical-detail explanation for ctg-fetal-monitoring. Checked the assessment, management-decision and follow-up statements in that section against this source. This does not certify all pre-existing regimens, calculations or recommendations in the module. Additional admission/discharge check 18 October 2026 (limited to the following): CTG interpretation in the whole clinical context and escalation for maternal/fetal concerns; no discharge based on one trace snapshot.

Scope: additional clinical-detail explanation for ptl-threatened, ptl-established. Checked the assessment, management-decision and follow-up statements in that section against this source. This does not certify all pre-existing regimens, calculations or recommendations in the module. Additional admission/discharge check 18 October 2026 (limited to the following): Suspected versus diagnosed preterm labour, ≥30-week cervical length >15 mm or appropriate fFN ≤50 ng/mL discussion of home care; unavailable testing means treat as diagnosed; membrane/infection/bleeding and fetal concerns override low-risk-test reassurance.

Scope: additional clinical-detail explanation for pprom. Checked the assessment, management-decision and follow-up statements in that section against this source. This does not certify all pre-existing regimens, calculations or recommendations in the module. Additional admission/discharge check 18 October 2026 (limited to the following): Initial hospital observation and individual selection for later home surveillance, rapid-return access and infection/labour/bleeding/fetal warnings.

Scope: additional clinical-detail explanation for multiples. Checked the assessment, management-decision and follow-up statements in that section against this source. This does not certify all pre-existing regimens, calculations or recommendations in the module. Additional admission/discharge check 18 October 2026 (limited to the following): Chorionicity-specific specialist surveillance, preterm/maternal/fetal complications and transfer/birth planning, without a universal uncomplicated admission week.

Scope: additional clinical-detail explanation for fgr. Checked the assessment, management-decision and follow-up statements in that section against this source. This does not certify all pre-existing regimens, calculations or recommendations in the module. Additional admission/discharge check 18 October 2026 (limited to the following): Current primary patient information reviewed for specialist growth/Doppler surveillance and birth planning. No universal scan interval or single-test home-discharge threshold added.

Scope: additional clinical-detail explanation for reduced-fetal-movements. Checked the assessment, management-decision and follow-up statements in that section against this source. This does not certify all pre-existing regimens, calculations or recommendations in the module. Additional admission/discharge check 18 October 2026 (limited to the following): Discharge only after appropriate assessment and review of ongoing concern; indicated ultrasound normally within 24 hours of request; return for every recurrence.

Scope: additional clinical-detail explanation for hdp-postpartum. Checked the assessment, management-decision and follow-up statements in that section against this source. This does not certify all pre-existing regimens, calculations or recommendations in the module. Targeted medication audit: Table 1 offers treatment for persistent BP >140/90 in gestational hypertension, target ≤135/85; after 37 weeks stable-patient birth timing is agreed with the woman and senior obstetrician. The former false “NICE severe-only” comparison was removed. Additional admission/discharge check 18 October 2026 (limited to the following): Admission for severe BP or maternal/fetal concerns; all three postnatal PE transfer criteria (no symptoms, BP ≤150/100, bloods stable/improving); treated BP every 1–2 days up to 2 weeks, untreated day 3–5/alternate days if abnormal, 2-week treatment and 6–8-week review, persistent proteinuria/3-month renal review. Methyldopa stopping and BP reduction thresholds checked.

Additional full-primary-HTML check for trimester guide: NG201 1.1/1.2 booking and 10 nulliparous/7 parous contacts, baseline CBC/group/Rh and offered infection/haemoglobinopathy screening, 11+2–14+1 dating and 18+0–20+6 anomaly scan, 28-week CBC/antibodies/Rh care, BP/proteinuria each routine face-to-face appointment, fundal-height assessment after 24 weeks, risk-driven scans and no routine ultrasound after 28 weeks in uncomplicated singleton pregnancy, presentation after 36 weeks and follow-up of abnormal results. These are labelled UK recommendations, not a full verification of every ANC medication or national policy.

Scope: additional clinical-detail explanation for uti-pyelonephritis. Checked the assessment, management-decision and follow-up statements in that section against this source. This does not certify all pre-existing regimens, calculations or recommendations in the module. Additional admission/discharge check 18 October 2026 (limited to the following): Pregnancy lower-UTI immediate treatment, culture-based review and reassessment if not improving; do not apply the nonpregnant delayed-prescription pathway.

Scope: additional clinical-detail explanation for uti-pyelonephritis. Checked the assessment, management-decision and follow-up statements in that section against this source. This does not certify all pre-existing regimens, calculations or recommendations in the module. Additional admission/discharge check 18 October 2026 (limited to the following): Pyelonephritis referral/admission with sepsis, dehydration/unable oral treatment or pregnancy risk; review IV therapy by 48 hours and step-down when appropriate. The app retains separately labelled ACOG initial inpatient pregnancy/14-day-total treatment.

Scope: additional clinical-detail explanation for maternal-sepsis. Checked the assessment, management-decision and follow-up statements in that section against this source. This does not certify all pre-existing regimens, calculations or recommendations in the module. Additional admission/discharge check 18 October 2026 (limited to the following): Sepsis risk escalation and immediate hospital assessment/transfer when severe illness suspected; home care requires recovery and an explicit source/result/antimicrobial plan.

Scope: additional clinical-detail explanation for gbs. Checked the assessment, management-decision and follow-up statements in that section against this source. This does not certify all pre-existing regimens, calculations or recommendations in the module. The page explicitly says its related guideline update is in progress; do not imply universal screening policy or a 2026 guideline edition.

Recommendations 1.18.1–1.18.5: no routine anti-D up to 11+6 weeks; offer to RhD-negative patients having medical or surgical management at 12+0–12+6 weeks, consider for heavy/recurrent threatened bleeding at that gestation. Corrected blanket all-loss anti-D wording; applicability to local Indian policy requires review. No claim to verify induced-abortion regimens. Additional admission/discharge check 18 October 2026 (limited to the following): Current gestation- and treatment-specific RhD criteria reviewed; discharge care points defer to that exact pathway rather than inventing one universal dose for miscarriage/abortion.

Checked the 50 mg/m² IM initial dose, day-4/day-7 hCG assessment, ≥15% fall criterion and senior reassessment before further doses. The document records a next review date of 30 September 2026, already past at this check; current local protocol should be confirmed. NICE national criteria are used for patient selection and the differing size thresholds are shown in a conflict block. This is a limited protocol check, not certification of the entire ectopic module.

Loading and maintenance doses, 24-hour stopping rule, recurrence ceiling, urine/reflex/respiratory monitoring and toxicity management.

10% strength, adult initial 1 g IV dose over at least 5 minutes for magnesium toxicity/severe hypocalcaemia; ECG and extravasation precautions.

PPH treatment 5–10 IU slow IV with 20 IU/L over 2 hours, total 60 IU ceiling; separate from prophylaxis and augmentation. Pump rates in the app are explicitly calculated.

Heavy abnormal uterine bleeding: 1 g three times daily, up to four times daily, at most 5 days, and renal/thrombotic cautions.

Term-labour induction/augmentation dose increments, pump-compatible dilution, 20 milliunits/minute regimen ceiling, contraction/fetal monitoring and rapid-bolus risk.

Refractory postpartum bleeding section: 250 micrograms/mL, 250 micrograms deep IM, 15–90-minute repeat intervals and 2 mg/eight-dose maximum; distinguished from the abortion section.

0.2 mg/mL, IM 0.2 mg repeat at 2–4-hour intervals, IV and hypertension precautions, and breastfeeding interruption in the label. No unsupported cumulative maximum added.

200–500 micrograms IM; severe-haemorrhage slow-IV 250–500 micrograms, optional dilution to 5 mL, and vascular/hypertension contraindications. Ergometrine distinguished from methylergometrine.

800-microgram SL PPH rescue dose, tablet strengths, route-specific labour-induction intervals and oxytocin separation.

Scanned primary PDF pages 103–104 examined by OCR and visual review: labetalol prose sequence/cumulative 300 mg, sustained-release nifedipine 10 mg twice daily/max 80 mg, and internal prose/flowchart differences for acute nifedipine and labetalol. The app exposes rather than merges the differences.

100 mg twice daily with increments, divided higher dosing, 2400 mg/day limit and beta-blocker cautions.

20 mg reconstituted/diluted to 10 mL (2 mg/mL), 5 mg over 2–4 minutes, 20-minute reassessment and cumulative 20 mg bolus regimen.

10 mg every 15 minutes up to 40 mg loading, 20 mg every 6 hours, 48-hour duration and maternal hypotension/concurrent-drug cautions. This is not the hypertension row.

250 mg twice/three times daily, slow increments, 3 g/day maximum, hepatic/depression cautions. NICE NG133 supplies the separate postpartum stopping recommendation.

Standard-weight prophylaxis table, duration based on risk, renal adjustment and neuraxial cautions. 2015 guideline, not represented as a new 2026 edition. Additional admission/discharge check 18 October 2026 (limited to the following): Repeat postpartum bleeding-versus-thrombosis risk assessment and documented prophylaxis indication/duration rather than a universal LMWH course.

Empiric anticoagulation pending objective exclusion, booking-weight LMWH, unfractionated-heparin 80 units/kg and 18 units/kg/hour with monitoring, life-threatening PE specialist reperfusion and treatment duration. 2015 edition. Additional admission/discharge check 18 October 2026 (limited to the following): Acute VTE treatment continued through pregnancy, at least 6 weeks postpartum and ≥3 months total; self-injection/sharps teaching and outpatient review; no automatic outpatient clearance for suspected/unstable PE.

Weekly 500 mg titration to 2 g/day, with meals, renal/acute-illness precautions; NICE NG3 separately provides pregnancy selection and targets.

Individualised once/twice-daily subcutaneous dosing, U-100 matching devices, NEVER-IV instruction and compatible insulin mixing order; no universal GDM starting dose invented.

Recommendation 1.9/type-and-regimen evidence: IM dexamethasone or betamethasone total 24 mg; four 6 mg dexamethasone doses 12 hours apart or two 12 mg betamethasone doses 24 hours apart. NICE NG25 supplies gestational and repeat-course criteria.

Adult cefazolin 2 g, 3 g at weight ≥120 kg, four-hour redosing and caesarean severe-beta-lactam-allergy alternative clindamycin plus gentamicin. 2013 standard; formulation preparation separately cross-checked against the cefazolin product label.

Source-specific combinations and durations for chorioamnionitis, endometritis and septic miscarriage; GBS ampicillin 2 g then 1 g every 4 h until delivery. Regional guidance is labelled; local resistance and culture review remain required. Additional admission/discharge check 18 October 2026 (limited to the following): Intra-amniotic infection/postpartum endometritis clinical improvement, IV reassessment and indication-specific course; no blanket prolonged oral antibiotics after uncomplicated response.

Cross-check of ampicillin 2 g IV then 1 g every 4 h until delivery, distinct from penicillin G million-unit dosing. This CDC aid states it is based on 2010 guidance; the Malaysian national guideline also confirms the regimen.

Adult 5–6 mg/kg daily, 40 mg/mL presentation, 100 mL adult infusion over 30 minutes and renal/ototoxicity/compatibility precautions; obstetric combination choice from the national infection guideline.

500 mg/100 mL over 30 minutes, every-8-hour adult dosing, switch to oral, severe hepatic reduction and interactions. Syndrome duration supplied separately by the infection guideline.

Inpatient pyelonephritis treatment, culture-directed therapy, 14-day total treatment and inadequate renal-parenchymal coverage from nitrofurantoin/fosfomycin.

Recommendation 27: <12-week mifepristone 200 mg followed 24–48 hours later by misoprostol 800 micrograms; route options and no fabricated universal maximum for repeat doses. India legal/service eligibility remains separate.

25 micrograms orally every 2 hours or 50 every 4 hours, 200 micrograms/24-hour ceiling, hospital monitoring, ≥4-hour separation from oxytocin, and no casual tablet splitting.

Primary 2024 RCOG/BJOG guideline (DOI 10.1111/1471-0528.17739) full PDF checked via an accessible copy because the publisher returned 403. Checked executive recommendations, section 7.1 and Appendix III: oral/IV ondansetron schedules, thiamine 100 mg three times daily or parenteral vitamin B, and the explicit example of 100 mg parenteral thiamine before dextrose. This does not certify the entire HG module. Copy read: https://www.missionmrcog.com/home/images/Library/Greentop_Guidelines/2024/Nausea%2C_vomiting_in_pregnancy_%26_hyperemesis_gravidarum%2C_UPDATE_2024.pdf Appendix III also checked for promethazine 12.5–25 mg every 4–8 hours and metoclopramide 5–10 mg every 8 hours; 0.9% saline with potassium guided by daily electrolytes. Thiamine 100 mg/2 mL and 30-minute very-slow IV administration cross-checked against MSF https://medicalguidelines.msf.org/en/viewport/EssDr/english/thiamine-vitamin-b1-injectable-16683171.html .

Specific delayed-release product: day-by-day escalation from two bedtime tablets to four/day, swallowing/empty-stomach instructions, scheduled use and taper.

Hb/weight total-need table, 20 mg/kg and 1000 mg infusion limits, ≥7-day spacing, saline-only dilution, ≥15-minute infusion for >500 mg, ≥30-minute observation, phosphate and pregnancy cautions. Additional admission/discharge check 18 October 2026 (limited to the following): At least 30-minute monitored observation after each infusion and reaction assessment; completing an infusion alone does not clear anaemia/bleeding for home care.

LNG 1.5 mg, 5-day window with time-related effectiveness, repeat if vomiting within 3 hours, contraception restart/backup and pregnancy-test follow-up. Additional admission/discharge check 18 October 2026 (limited to the following): Emergency-contraception instructions, pregnancy testing and timing/backup distinction after ulipristal versus levonorgestrel.

Adult pregnancy IM adrenaline 500 micrograms every 5 minutes, refractory reaction after two appropriate doses, IV-infusion concentration/rate, fluids, steroid/antihistamine role and risk-based observation.

Adult compression/rhythm algorithm and adrenaline 1 mg IV/IO timing with repeat every 3–5 minutes; pregnancy follows the usual drug/defibrillation dosing with specific modifications.

Manual left uterine displacement above 20 weeks, reversible/obstetric causes and early/as-soon-as-possible resuscitative hysterotomy at the arrest location, rather than waiting for a 4-minute trigger.

Treat <4 mmol/L, oral carbohydrate if safe, IV glucose 20 g using 10%/20% solutions, IM glucagon 1 mg, repeat glucose checks and subsequent carbohydrate/insulin review. Additional admission/discharge check 18 October 2026 (limited to the following): Education, precipitating-cause review, ongoing glucose checks and diabetes-team review before discharge after severe/recurrent hypoglycaemia.

Pregnancy/euglycaemic DKA cautions; soluble insulin 50 units/50 mL, 0.1 units/kg/hour, no routine bolus, glucose/ketone/electrolyte monitoring, potassium table, resolution and IV-to-SC overlap. Additional admission/discharge check 18 October 2026 (limited to the following): Resolution blood ketones <0.6 mmol/L and venous pH >7.3, clinical recovery/eating and safe IV-to-subcutaneous overlap; glucose alone does not establish resolution; diabetes education and follow-up.

MSF peripheral TARTRATE-based 0.1 microgram/kg/min starting dose, dilution to 100 micrograms TARTRATE/mL, pump formula, titration/ceiling and salt-versus-base distinction; SMFM supplies maternal-sepsis vasopressor choice.

Adult massive-PE 100 mg over 2 hours, reconstitution to 1 mg/mL, bleeding contraindications/monitoring and post-infusion heparin criteria. Not the stroke regimen or an automatic pregnancy recommendation.

Timed rescue: lorazepam up to 4 mg in divided IV doses, repeat benzodiazepine at 10 minutes if necessary, levetiracetam 60 mg/kg capped at 4500 mg and ICU escalation; levetiracetam preparation separately cross-checked against the Keppra concentrate SmPC https://www.medicines.org.uk/emc/product/2296/smpc (100 mg/mL, at least 100 mL compatible fluid, 15-minute infusion); the status load remains explicitly off-label.

Five-minute convulsive-status recognition, first-line benzodiazepine and second-line IV antiseizure options/escalation.

4Ts assessment, atonic-PPH oxytocin, additional uterotonic choice, compression, source control, tamponade and urgent surgical escalation. WHO 2025 supplies the newer treatment-recognition trigger. Additional admission/discharge check 18 October 2026 (limited to the following): Haemorrhage resuscitation, cause control, organ/urine/bleeding monitoring and surgical escalation reviewed as the basis for recovery; no universal discharge Hb value or routine take-home TXA/uterotonic course inferred.

Earlier PPH treatment trigger: ≥300 mL with abnormal vital signs in addition to the traditional 500 mL threshold; avoid waiting for 1000 mL after caesarean before treating compromise.

Scoped sections: shoulder dystocia (7.5), uterine rupture (3.3), APH (chapter 3), ectopic emergencies, maternal resuscitation and PPH/inversion. 2019 edition, PDF exported April 2025; not represented as a new 2026 edition.

Elevation of presenting part, positioning, minimal cord handling, bladder 500–750 mL instillation for delay/transfer, emptying before birth and birth urgency. 2014 edition, scoped check.

Immediate replacement with concurrent resuscitation, do not remove attached placenta before reduction, temporarily stop then restart uterotonics, and surgical rescue. Additional admission/discharge check 18 October 2026 (limited to the following): Reduction, recurrence risk with manipulation, uterotonic after restoration and continuing haemorrhage/urine monitoring; reduced uterus and no recurrent inversion required before home recovery is considered.

Primary 2026 statement: multidisciplinary resuscitation, haemostasis, physiology-guided support, fluid-overload risk and no routine unproven A-OK cocktail.

Urgent laparoscopy, Doppler does not exclude torsion, detorsion and tissue preservation regardless of appearance in adolescents; adult/postmenopausal extrapolation explicitly limited.

Sepsis without obligatory fever, cultures without antibiotic delay, early broad-spectrum treatment, 1–2 L balanced crystalloid in 3 hours with response-guided reassessment, norepinephrine and uterine source control. Additional admission/discharge check 18 October 2026 (limited to the following): Prompt source identification/control and organ support; comprehensive ongoing physical/cognitive/emotional support for pregnant/postpartum sepsis survivors.

Hypertension initial 5 mg with volume/renal caution, 40 mg/day maintenance ceiling, creatinine/potassium and pregnancy/feeding warnings. NICE NG133 supplies the separately cited postpartum recommendation.

Terbutaline 250 micrograms SC (0.5 mL of 0.5 mg/mL) ten minutes before ECV; pulse check at five minutes, CTG, cardiac contraindication, diabetes/PE cautions and anti-D. Additional admission/discharge check 18 October 2026 (limited to the following): Institutional ECV monitoring/complication pathway checked; no routine take-home tocolytic course inferred.

GBS maternal IV loading 3 g (5 million units) then 1.5 g (2.5 million units) every four hours until birth; >1.2 g administration at least one minute/300 mg. Section 6.6: each 1.2 g vial in at least 8 mL for injection or 20 mL for infusion; ~0.8 mL powder displacement.

Adult 300–600 mg/day initial, then 50–150 mg/day when controlled; renal reductions and hepatic/agranulocytosis warnings. The regimen explicitly distinguishes the general adult range from pregnancy-specific lowest-effective-dose selection in RCOG GTG76.

Adult 20–60 mg/day initial divided two/three times; 5–15 mg/day maintenance; pregnancy lowest-effective-dose/no block-and-replace, pancreatitis, marrow and hepatic warnings. RCOG supplies pregnancy timing and PTU conversion.

Full open-access primary statement: PTU loading/maintenance, caution with beta-blockade/cardiomyopathy, propranolol 60–80 mg every four hours, hydrocortisone 100 mg load then 50 mg four times/day, iodine at least one hour after thionamide, SSKI five drops four times/day, prompt de-escalation and failure review. Preparation companions: Panpharma hydrocortisone 100 mg powder SmPC https://www.medicines.org.uk/emc/product/9377/smpc and SSKI 1 g/mL https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ca1d3449-ea29-49a4-8863-365ec95f1553 . Additional admission/discharge check 18 October 2026 (limited to the following): Systemic/haemodynamic/mental recovery and transition to maintenance before discharge; no pregnancy-inappropriate radioiodine recommendation added.

Recommendation A.2.1: prevention 30–60 mg elemental iron plus 400 micrograms folic acid daily; anaemia treatment 120 mg elemental iron with 400 micrograms folic acid until Hb normal, then prevention. Limited dose-scope check through the primary WHO text indexed by NCBI; not a revalidation of every 2016 threshold.

Low-dietary-intake population: 1.5–2 g elemental calcium/day in three divided doses, preferably with meals; separate iron, no established optimal starting gestation. Primary WHO recommendation table checked through NCBI.

Adult 10 mg up to three times/day, daily limit 30 mg or 0.5 mg/kg, ≥6-hour interval including after vomiting, maximum five days, renal/hepatic reductions and extrapyramidal contraindications. RCOG Appendix III separately supplies pregnancy/HG 5–10 mg every eight hours.

Full primary PDF: UDCA starts 10–15 mg/kg/day in two/three doses, titration to at most 21 mg/kg/day for symptoms. Birth timing and fetal-risk counselling are distinct from symptom treatment; RCOG patient guidance separately confirms no demonstrated stillbirth prevention. Additional admission/discharge check 18 October 2026 (limited to the following): Bile-acid-informed obstetric planning and the limitations of symptom treatment; do not substitute UDCA for surveillance/birth decisions.

One sterile 52 mg system, trained insertion, contraindications; 8-year contraception, 5-year HMB then symptom review and maximum 8 years if continued, 4-year UK-labelled HRT endometrial protection. Indication-specific durations are not interchangeable. Additional admission/discharge check 18 October 2026 (limited to the following): Procedure recovery, perforation/infection/pregnancy warnings and method-specific review; no generic routine admission inferred.

Initial letrozole 2.5 mg daily cycle days 2–6 for five days; day-one definition, pregnancy test if no period, response monitoring and reassessment. This named starting pathway does not establish a universal maximum for escalation.

21 active 30-microgram/150-microgram tablets plus 7 inactive in a 28-day pack; one tablet daily, no gap between packs, seven-day backup for a later start and eligibility contraindications. No claim to update every missed-pill algorithm.

50-microgram/24-hour patch starting example, replaced every three/four days; application site/rotation, progestogen need with uterus, ongoing benefit-risk review and contraindications.

Micronised progesterone 200 mg for 12–14 days/month sequentially or 100 mg daily continuously at standard oestrogen doses; higher oestrogen requires proportional protection; unscheduled bleeding review. Does not certify all menopause therapy.

1500 IU/300 micrograms in 2 mL, product-specific IM/IV routes, routine 28–30-week prophylaxis, postnatal as soon as possible within 72 hours (give if delayed), 15 mL fetal-RBC coverage and FMH-based additional dose, maternal identity and route precautions.

Contraindication in mothers in pre/postnatal periods and late pregnancy; neonatal haemolytic anaemia, hyperbilirubinaemia/kernicterus warning. Used to flag a conflict with an older local obstetric-cholestasis pathway, not to recommend this drug routinely.

Older local pathway proposes off-label menadiol 10 mg/day from 34 weeks, discusses prolonged PT and neonatal risks. Its age and conflict with the product contraindication are displayed; it is not the app default.

Pregnant-patient seven-day nitrofurantoin and cefalexin schedules, modified/immediate-release distinction, renal eligibility, avoid-at-term and upper-UTI exclusions; not the adjacent three-day nonpregnant table.

Stage-specific benzathine penicillin: early 2.4 million units IM with optional pregnancy second dose one week later; late/unknown weekly three-dose course; >9-day interval in pregnancy restarts course, desensitisation and neonatal planning. Bicillin L-A prefilled product identity/deep-IM-only warning checked against https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=012d46f1-d0a0-4676-a879-cd320297ab16 ; do not convert nominal syringe size into a generic reconstitution recipe. Neonatal dependency corrected against CDC congenital-syphilis guidance https://www.cdc.gov/std/treatment-guidelines/congenital-syphilis.htm : evaluation/therapy is scenario- and age-specific; the old all-ten-days every-12-hour instruction is not retained.

18–24 million units/day IV, 3–4 million every four hours or continuous, for 10–14 days; pregnancy penicillin desensitisation. Preparation of the selected 4-million-unit/2.4-g sodium dose cross-checked against the registered 1.2-g vial SmPC, https://www.medicines.org.uk/emc/product/102025/smpc .

1% clotrimazole vaginal cream 5 g/day and pregnancy-specific seven-day topical azole recommendation; avoid oral fluconazole in pregnancy and evaluate persistent symptoms.

One 3 mg vaginal tablet, possible single repeat after six/eight hours, total maximum 6 mg; ≥6-hour oxytocin separation, formulation/route identity, uterine scar/fetal/obstetric contraindications and continuous clinical/fetal assessment.

Primary paper sections 4–5: suction evacuation with ultrasound guidance and haemorrhage support, no routine second curettage, histology and referral, hCG every one/two weeks then partial-mole confirmatory test at one month versus complete-mole monthly six months; updated FIGO plateau/rise/histological choriocarcinoma criteria. Not a chemotherapy-dose audit. Additional admission/discharge check 18 October 2026 (limited to the following): Post-evacuation hCG every 1–2 weeks; partial mole confirmatory test at 1 month after normalisation; complete mole monthly for 6 months after normalisation; results/service registration and contraception.

Postoperative indication/schedules and pregnancy caution (avoid first trimester; not recommended for NVP) checked. Displayed as a source/indication-specific conflict with RCOG GTG69, not silently combined with its HG doses.

Primary WHO calendar checked: minimum eight contacts within 12 weeks then 20/26/30/34/36/38/40, one/two/five contacts by trimester, additional risk-driven care and ultrasound before 24 weeks. WHO current healthy-pregnancy page also continues the eight-contact recommendation.

Current official programme page checked: minimum four ANCs, first-trimester registration and baseline package; PMSMA designated ninth-of-month second/third-trimester specialist care and extra high-risk follow-up. Displayed alongside WHO/NICE rather than replacing them silently.

Full primary PDF sections 4.4–4.6: universal first-contact testing, negative-test repeat at 24–28 weeks ≥4 weeks later, late presentation >28 weeks tested at first contact; 75 g glucose in ~300 mL within 5–10 min regardless of last meal, two-hour ≥140 mg/dL, plasma-calibrated method, vomiting within 30 min repeats next day/referral; six-week postpartum OGTT and annual screening. The document is labelled 2018, and its historical claim equating other organisations’ thresholds is not adopted. Additional admission/discharge check 18 October 2026 (limited to the following): India post-GDM glucose follow-up distinguished from NICE fasting plasma glucose at 6–13 weeks; no mixed diagnostic method or universal postpartum treatment stop applied to pre-existing diabetes.

Primary WHO recommendation text indexed by NCBI: midstream urine culture is preferred for asymptomatic bacteriuria; dipstick protein assessment is not a substitute. Direct page currently has a browser challenge, so verification is limited to the primary indexed text.

Primary patient guidance opened: UK does not universally screen; a positive urine/swab result and risk history inform intrapartum antibiotics. Used to avoid presenting a universal third-trimester GBS test as mandatory in every health system.

Maternal/newborn transfer assessment, first void and effective feeding, handover, support/safeguarding, first midwife visit within 36 hours after transfer, postnatal danger symptoms. Full recommendations page read.

Normal-delivery discharge not less than 48 hours: full primary SOP PDF normal-delivery/discharge passages read. Corroborated by NHM CEmONC 2024 Part 1, chapter 8. This does not define a universal post-caesarean or complicated-case stay.

Official WHO summary read: at least 24-hour facility care after birth; additional contacts at 48–72 hours, 7–14 days and week 6; individual assessment/support. Summary facts only, not a claim that the full 242-page PDF was reviewed.

Full primary patient recovery page read: pain control, wounds, activity/VTE, urinary/bowel and infection warning signs, adult support and no driving/important decisions during the first 24 hours after general anaesthesia. Used as general recovery/handover principles, not operation-specific discharge thresholds.

Full primary recommendations read, focusing on critical-care-to-ward transfer: structured written handover, shared plan, monitoring, rehabilitation and receiving-team capability. Step-down is distinct from home discharge; no universal organ-support discharge cutoff is asserted.

Full primary PDF downloaded; term prelabour rupture, selected expectant care and induction around 24 hours, temperature/return precautions, maternal post-birth assessment and newborn observation after prolonged membrane rupture checked. This is scoped to the implemented admission/transfer recommendations.

Full primary recommendation page read for postmenopausal bleeding, cervical/ovarian/endometrial concern and referral/result follow-through. Supports triage/referral only; it does not supply chemotherapy or tumour-specific postoperative discharge regimens.

Primary recommendations read: unwell patients receiving anticancer treatment need immediate assessment and suspected neutropenic sepsis is an acute emergency; only a trained specialist using an appropriate risk assessment selects outpatient care.

Primary public information read: expected recovery, bleeding/pain, infection or continuing-pregnancy concerns, follow-up access and contraceptive counselling; used with WHO abortion guidance, without inventing a mandatory visit after every uncomplicated abortion.

Full public page read: usual outpatient/day-case pathway, pain/bleeding, infection/perforation concerns, recovery after anaesthesia and biopsy-result communication.

Primary information read: mild OHSS may be managed at home; uncontrolled pain/vomiting, failure to improve or inability to attend monitoring can require admission; urine/fluid/renal/thrombosis assessment and avoiding NSAIDs. Edition is 2016, not a newly issued 2026 guideline; no universal anticoagulant duration is imposed.

Primary information read: individualised admission by bleeding/history/access, urgent attendance for bleeding/pain/contractions, specialist PAS/vasa praevia birth planning and postoperative/fertility counselling. No universal asymptomatic admission week is inferred.

Primary full page read: usual home recovery, expected bleeding/discharge, restrictions during recovery, heavy bleeding/offensive discharge/persistent pain and tracking biopsy results.

Full primary PDF observation/discharge table read: narrowly selected 2-hour fast-track after resolution, ≥6 hours for two IM doses or previous biphasic reaction, ≥12 hours for severe/high-risk/access scenarios; action plan, auto-injectors/training and allergy referral. Pregnancy also needs obstetric/fetal assessment; generic timing is not automatic maternity clearance.

Primary recommendation table indexed at NCBI Bookshelf checked: postpartum diagnosed anaemia 120 mg elemental iron plus 400 micrograms folic acid daily until Hb normal; preventive 6–12 weeks is a separate indication. Direct table retrieval presented a browser check, so this is a limited primary-text check. Elemental preparation and Hb response monitoring reuse med-who-anc-dose, not a newly verified universal product label.

Full primary oral monograph read: adult 1 g 3–4 times daily, maximum 4 g/day, ≥50 kg adult table, 500 mg tablets, duration according to response, hepatic caution and pregnancy/breastfeeding. Pain chapter also checked for 6–8-hour interval. Smaller adults require an individual weight-based prescription.

Full primary monograph read: pain 200–400 mg, maximum 1200 mg/day; postoperative every 8 hours, maximum 8 days; meals/formulations, renal/GI/bleeding/dehydration/infection contraindications and interactions, short-term breastfeeding. New card restricted to postpartum/nonpregnant care; OHSS renal caution also from RCOG.

Full institutional guideline read: documented postoperative place of care, fluids/analgesia/antibiotics/VTE/catheter plan, organ-injury assessment, pre-discharge debrief, consultation in a few weeks, fertility/contraception and procedure-dependent long-term counselling. Used as a labelled local recovery pathway, not a universal subsequent-pregnancy delivery schedule.